Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
192.34(c) 207.99(c) 200.71(c) 200.07(c) 217.97(c) Last
3 471 975 5 654 538 3 316 490 2 916 347 6 152 397 Volume
+0.68% +8.14% -3.50% -0.32% +8.95% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 396 M - -
Net income 2021 -905 M - -
Net cash position 2021 756 M - -
P/E ratio 2021 -18,0x
Yield 2021 -
Sales 2022 4 834 M - -
Net income 2022 2 287 M - -
Net cash position 2022 1 936 M - -
P/E ratio 2022 7,96x
Yield 2022 -
Capitalization 16 480 M 16 480 M -
EV / Sales 2021 11,3x
EV / Sales 2022 3,01x
Nbr of Employees 792
Free-Float 98,5%
More Financials
Company
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline... 
More about the company
Ratings of Novavax, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about NOVAVAX, INC.
11/27NVAX ALERT : Investors with Substantial Losses Have Opportunity to Lead the Novavax, Inc. ..
BU
11/26Novavax developing vaccine that targets new COVID-19 variant
RE
11/26Novavax testing vaccine that targets new COVID-19 variant
RE
11/26Novavax - recent data from phase 2 trial lead us to believe that our vaccine is likely ..
RE
11/26Novavax Inc - Has Already Initiated Development Of A New Recombinant Spike Protein Base..
RE
11/26Novavax - will have new recombinant spike protein based on known genetic sequence of b...
RE
11/26Novavax statement on nu variant
RE
11/26IMPORTANT INVESTOR REMINDER : Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. Inv..
PR
11/26India resumes coronavirus vaccine exports to COVAX
RE
11/24INSIDER SELL : Novavax
MT
11/24Novavax Seeks Interim Authorization of COVID-19 Vaccine in Singapore
MT
11/24Novavax, Inc. Announces Submission to the Singapore Health Sciences Authority for Inter..
CI
11/24Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore
PR
11/23Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference
PR
11/18India allows export of 20 mln Novavax vaccine doses to Indonesia -document, source
RE
More news
News in other languages on NOVAVAX, INC.
08:35aLe nouveau variant Omicron se répand sur la planète
06:05aIsraël ferme ses frontières face au variant Omicron qui gagne l'Australie
11/27VARIANT OMICRON : possible de développer "très rapidement" un vaccin, affirme un
11/26Wall Street déstabilisée par le variant, forte chute pour le Dow Jones
11/26Wall Street ouvre en forte baisse, sauve qui peut face au variant
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 217,97 $
Average target price 260,60 $
Spread / Average Target 19,6%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.95.47%16 480
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431